

Quarterly Industry Update

As of August 31, 2013

Industry: Oncological Therapy

Industry Summary

Cogent Valuation identified publicly traded companies, IPOs, and recent M&A transactions within the Oncological Therapy industry, which provides a basis for market and transaction pricing that can be used by your firm in estimating market sentiment and its impact on your firm's value. Since August 31, 2012, the median 52-week share price return of the Oncological Therapy industry has decreased by -0.7%.

Comparable Public Company Key Statistics


Median 52-Week Return	-0.7%	Median EV/Revenue Multiple	2.7x	Median Price/Earnings Multiple	32.6x
Median 3-Year CAGR Return	24.7%	Median EV/EBITDA Multiple	9.9x	Median EV/Gross CF Multiple	22.6x

Comparable Public Company Market Price Returns (As of August 31, 2013)


	YTD	3 Month	1 Year	2 Year	3 Year	5 Year	2012	2011	2010	2009	2008
Agenus Inc.	-11.0%	-9.4%	-20.5%	8.2%	-7.6%	-19.0%	105.0%	-67.0%	57.8%	33.3%	-76.5%
Sunesis Pharmaceuticals, Inc.	14.5%	-10.8%	51.7%	76.2%	24.7%	-12.7%	259.0%	-62.5%	-51.4%	234.4%	-83.9%
Infinity Pharmaceuticals, Inc.	-47.1%	-31.3%	1.9%	64.3%	57.7%	20.2%	295.9%	49.1%	-4.0%	-22.7%	-16.3%
Oncolytics Biotech Inc.	-32.4%	1.5%	-0.7%	-16.4%	-3.9%	8.4%	0.5%	-41.8%	156.7%	115.7%	-29.6%
ArQule Inc.	0.0%	3.0%	-46.8%	-20.0%	-18.8%	-4.5%	-50.5%	-3.9%	59.1%	-12.6%	-27.2%
OncoGenex Pharmaceuticals, Inc.	-31.8%	-13.1%	-34.6%	-13.4%	-11.3%	9.0%	11.8%	-30.1%	-24.6%	642.7%	N/A
Curis, Inc.	27.7%	16.5%	-0.5%	17.0%	52.7%	20.3%	-26.7%	136.4%	-39.1%	333.3%	-23.5%
Spectrum Pharmaceuticals, Inc.	-31.5%	-6.7%	-36.0%	-5.3%	27.5%	35.0%	-23.5%	113.0%	54.7%	198.0%	-45.2%
Incyte Corporation	104.0%	52.9%	69.4%	45.2%	39.4%	27.1%	10.7%	-9.4%	81.8%	140.4%	-62.3%
AVEO Pharmaceuticals, Inc.	-73.7%	-17.2%	-77.9%	-64.7%	-37.4%	N/A	-53.2%	17.6%	N/A	N/A	N/A
SciClone Pharmaceuticals, Inc.	21.8%	9.1%	7.1%	5.9%	29.6%	28.6%	0.5%	2.6%	79.4%	214.9%	-64.1%
Median of Industry Public Companies	-11.0%	-6.7%	-0.7%	5.9%	24.7%	14.6%	0.5%	-3.9%	56.3%	169.2%	-45.2%

(Multiple year periods are calculated as the average annual return.)

Median Quarterly Revenue Growth of All Oncological Therapy Companies



Median Gross Profit, EBITDA, Net Income and Gross Cash Flow Margins



Median Public Company Multiples of the Oncological Therapy Industry

Date:	8/31/2011	11/30/2011	2/29/2012	5/31/2012	8/31/2012	11/30/2012	2/28/2013	5/31/2013	8/31/2013
EV/Revenues Multiple	3.3x	3.5x	2.8x	7.1x	4.9x	7.6x	6.2x	2.5x	2.7x
EV/EBITDA Multiple	9.9x	9.9x	10.3x	7.4x	5.3x	5.2x	5.3x	5.2x	9.9x
Price/Earnings Multiple	15.9x	16.0x	16.5x	9.5x	6.5x	10.0x	17.0x	37.0x	32.6x
EV/Gross Cash Flows Multiple	12.8x	10.6x	11.3x	7.1x	5.0x	7.1x	11.6x	21.2x	22.6x

Note: Valuation multiples are volatile due to few companies that have positive operating performance.

Quarterly Industry Update

As of August 31, 2013

Industry: Oncological Therapy




Industry Initial Public Offerings (dollars in millions, except share prices)

Offer Date	Company Name	Offer Price	Shares Offered	Amount Raised	Total Assets	Debt	LTM Revenues	LTM EBITDA	LTM Net Income	LTM Cash Flows
5/15/2013	Ambit Biosciences Corporation	\$8.00	8.1	\$65.0	\$12.4	\$3.1	\$19.0	(\$21.5)	(\$27.0)	N/A
1/28/2013	Stemline Therapeutics, Inc.	\$10.00	3.3	\$33.2	\$5.0	\$2.0	\$0.0	\$0.0	(\$6.3)	\$0.0
6/27/2012	Tesaro, Inc.	\$13.50	6.0	\$81.0	\$93.0	\$0.0	\$0.0	(\$23.2)	(\$23.2)	(\$23.2)
3/28/2012	Merrimack Pharmaceuticals, Inc.	\$7.00	14.3	\$100.1	\$85.3	\$0.0	\$34.2	(\$76.3)	(\$79.2)	(\$72.0)
1/26/2012	Verastem, Inc.	\$10.00	5.5	\$55.0	\$59.0	\$0.0	\$0.0	(\$13.6)	(\$13.7)	(\$13.5)
4/19/2011	Sagent Pharmaceuticals, Inc.	\$16.00	5.8	\$92.0	\$118.7	\$33.7	\$95.8	(\$16.1)	(\$21.5)	N/A
4/1/2011	Tranzyme, Inc.	\$4.00	13.5	\$54.0	\$18.2	\$12.9	\$9.5	(\$5.9)	(\$8.0)	N/A
2/11/2011	AcelRx Pharmaceuticals, Inc.	\$5.00	8.0	\$40.0	\$6.8	\$12.0	\$0.0	(\$11.7)	(\$14.3)	(\$11.2)
2/4/2011	Endocyte, Inc.	\$6.00	12.5	\$75.0	\$21.2	\$25.0	\$0.0	(\$20.3)	(\$20.1)	N/A
2/2/2011	Pacira Pharmaceuticals, Inc.	\$7.00	6.0	\$42.0	\$66.6	\$79.4	\$14.6	(\$18.8)	(\$27.1)	N/A
1/24/2011	Tibet Pharmaceuticals, Inc.	\$5.50	3.0	\$16.5	\$28.2	\$0.0	\$32.4	\$14.2	\$13.1	N/A
Median of All IPOs		nm	nm	\$55.0	\$28.2	\$3.1	\$9.5	(\$16.1)	(\$20.1)	(\$13.5)

Recent Merger and Acquisition Transactions for a Majority Stake (dollars in millions)

Transaction Date	Target	Acquirer	Transaction Size	% Bought
2/8/2013	YM BioSciences	Gilead Sciences	\$482.9	100%
6/14/2011	Chemgenex Pharmaceuticals	Cephalon	\$157.7	72%
5/12/2011	ZARS Pharma	Nuvo Research	\$36.5	100%
4/11/2011	Clinical Data	Forest Laboratories	\$1,162.0	100%
3/4/2011	BioVex	Amgen	\$1,000.0	100%
10/28/2010	Trubion Pharmaceuticals	Emergent BioSolutions	\$141.7	100%
10/15/2010	Abraxis BioScience	Celgene Corporation	\$3,659.6	100%
10/7/2010	ZymoGenetics	Bristol-Myers Squibb	\$938.2	100%
4/19/2010	Facet Biotech Corporation	Abbott Laboratories	\$747.4	100%
2/10/2010	LEAD Therapeutics	BioMarin Pharmaceutical	\$107.1	100%
12/23/2009	Neurogen	Ligand Pharmaceuticals	\$18.4	100%
11/16/2009	Proteolix	Onyx Pharmaceuticals	\$858.9	100%
11/12/2009	Peplin	LEO Pharma	\$272.4	100%
8/31/2009	Medarex	Bristol-Myers Squibb	\$2,325.2	98%
6/29/2009	Arana Therapeutics	Cephalon International	\$163.4	80%
6/1/2009	VGX Pharmaceuticals	Inovio Biomedical	\$49.5	100%
4/27/2009	BiPar Sciences	Sanofi-Aventis	\$500.0	100%
Median of All Transaction Targets			\$482.9	100%

Size of Merger and Acquisition Transactions (dollars in millions)



Disclosures and Limitations: This research report is for informational and discussion purposes only. This report and any information presented herein is not investment advice of any kind to any person and does not constitute a recommendation as to the purchase or sale of any interests or as to any other course of action. General, financial, and statistical information concerning the details of this report and related industry are from sources Cogent Valuation believes to be reliable. Cogent Valuation has accurately reflected such information in this research report; however, Cogent Valuation makes no representation as to the sources' accuracy or completeness and has accepted this information without further verification. Neither all nor any part of the content of this report may be conveyed to the public through advertising, public relations, news, sales, mail, direct transmittal, or other media without the prior written consent of Cogent Valuation. Cogent Valuation's research is as of the date reported herein. Cogent Valuation has no affiliation with any of the companies comprising the composite used as a basis for research in this report, nor does Cogent Valuation hold any investments in the companies listed herein. The content of this report may be used, in part, as a basis for any work that Cogent Valuation performs for you in the future at the sole discretion of Cogent Valuation. THIS REPORT IS NOT TO BE USED OR CONSIDERED UNDER ANY CIRCUMSTANCE BY ANYONE AS INVESTMENT ADVICE. This industry research is provided at no charge to Cogent Valuation's clients. Research or detailed information not covered in this report can be obtained for a fee. Contact Steven Kam at 415-392-0888 for additional information or questions in connection with this research report. Copyright © 2013 Cogent Valuation. All Rights Reserved.